FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns treating interstitial pulmonary disease associated with systemic sclerosis. Disclosed is the use of a compound represented by the following chemical formula:
Chemical formula 1
,
or a pharmaceutically acceptable salt thereof for preventing or treating and interstitial pulmonary disease associated with systemic sclerosis (SSc-ILD).
EFFECT: said application provides a double effect, relieving skin coarsening in interstitial pulmonary disease associated with systemic sclerosis, and improving pulmonary function.
3 cl, 9 dwg, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FIBROSIS | 2022 |
|
RU2829908C2 |
| METHODS OF INHIBITING LEUCOTREEN-A-HYDROLASES | 2014 |
|
RU2686101C2 |
| 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR TREATMENT OF INFLAMMATORY AIRWAY DISEASES | 2020 |
|
RU2830122C2 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| AGENT FOR PULMONARY FIBROSIS CONTAINING PYRAZOLE DERIVATIVE | 2021 |
|
RU2817989C1 |
| METHOD OF TREATING SCLERODERMA | 2008 |
|
RU2530561C2 |
| THERAPEUTIC AGENT FOR FIBROSIS | 2016 |
|
RU2729630C2 |
| MATERIALS AND METHODS OF TREATING CHRONIC FIBROUS DISEASES | 2006 |
|
RU2446825C2 |
| COMPOSITION FOR RECOVERY OF NORMAL TISSUE FROM FIBROUS TISSUE | 2011 |
|
RU2650796C2 |
| ANTIFIBROGENIC COMPOUNDS, METHODS AND USE THEREOF | 2014 |
|
RU2726416C2 |
